About: Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 July 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2005 (fr) наукова стаття, опублікована в серпні 2005 (uk) im August 2005 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 11 July 2005 (en) 2005 թվականի հուլիսի 11-ին հրատարակված գիտական հոդված (hy) artículu científicu espublizáu en xunetu de 2005 (ast)
publication date	wds:Q56688854-09828A9A-3E51-4CAD-93BB-CDCE56A9DA29
publication date	2005-07-11 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56688854-43ADD9AF-DFA3-438F-BF00-A6DA93AA1B92
language of work or name	English
author name string	wds:Q56688854-5C62777C-DDF0-44F9-9AEE-45802F378AB0 wds:Q56688854-710C193F-B321-4485-8D8D-EC57643FFD52 wds:Q56688854-914C99CF-505E-4209-93E0-D0D21F0256CF wds:Q56688854-BFC2F7BC-48D6-450D-AB5E-678C20E5F150 wds:Q56688854-D4BDE19D-5748-4300-8E61-85238A9664F1 wds:Q56688854-DAC19A2B-2C94-4C03-A7E9-F2E30CD13053 wds:Q56688854-E839FB51-910A-414C-99E1-88BAED026B7C wds:Q56688854-EFE53F00-5913-4E1F-8183-F4F7A1352C10 wds:Q56688854-FFBADF6C-4059-4BE3-9A4F-EF5EA233BA4C
author name string	José Baselga Jean Bourhis Pere Gascón Hernán Cortés-Funes Andreas Harstrick Ricardo Hitt Nadia Amellal José M Trigo Jacques Tortochaux
rdfs:label	Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head (en) Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head (nl)
skos:prefLabel	Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head (en) Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head (nl)
name	Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head (en) Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head (nl)
author	wds:Q56688854-D180D6E4-B53A-4A86-B6A6-808141E71D50
author	André M. Eckardt
title	wds:Q56688854-BF9A244D-BB23-47FA-AD7F-A67518EE823A
title	Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (en)
page(s)	wds:Q56688854-24BB9515-CB42-4CDC-9562-36FDE49B14D2
page(s)	5568-5577
instance of	wds:Q56688854-FE8D7A5E-3A43-4554-8CDC-73E90C026479
instance of	scholarly article
main subject	wds:Q56688854-202F1F0F-4752-4D0C-96FC-82AF4229111E wds:Q56688854-53476C88-6895-4C6D-B118-8B8FF8005BC8 wds:Q56688854-72D58B12-529D-4D38-AB4E-8F409404C82D wds:Q56688854-A747AC6C-5F12-44B4-87BC-6D259DDA62D2 wds:Q56688854-CC06E2AE-B553-4C0C-93A8-619CAC8FD9DD wds:Q56688854-D7782F08-3AF2-4C44-91D1-445A11C15435 wds:Q56688854-E2E1E07B-1890-4737-BA9B-FDDBDAEAA779
main subject	platinum cetuximab monoclonal antibody antibody chemotherapy Patients squamous cell carcinoma
PubMed ID	wds:Q56688854-BC9EEB22-6B32-4285-9828-EB8174785001
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16009950
PubMed ID	16009950
published in	wds:Q56688854-74CF368A-FE30-4BB3-9D46-967B53C5F73B
published in	Journal of Clinical Oncology
issue	wds:Q56688854-1109B992-2223-48D3-9199-1E7DF84F0C95
volume	wds:Q56688854-E24E51A5-D45B-4397-833E-3B1FF252AEF7
issue	24
volume	23
DOI	wds:Q56688854-4FD9204F-C845-4CC6-B123-D451392ED0F6
DOI	http://dx.doi.org/10.1200/JCO.2005.07.119
DOI	10.1200/JCO.2005.07.119
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56688854
is cites work of	The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck Implications of EGFR PharmDx kit for cetuximab eligibility Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice Nanotechnology-based drug delivery systems for treatment of oral cancer: a review Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma Targeting EGFR resistance networks in head and neck cancer. Optimal treatment for recurrent/metastatic head and neck cancer. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414) Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck Targeted therapy in head and neck cancer Molecular changes in the multistage pathogenesis of head and neck cancer Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines Promising new molecular targeted therapies in head and neck cancer Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer Understanding resistance to EGFR inhibitors-impact on future treatment strategies Combination drug delivery approaches in metastatic breast cancer Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Targeting CD137 enhances the efficacy of cetuximab.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software